Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Znomics, a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, has appointed Mark Philip as its new president and CEO.
Subscribe to our email newsletter
Dr Philip succeeds Richard Sessions, Znomics co-founder and interim CEO, who will remain as a consultant to the company and as an active member of Znomics’s board of directors.
Most recently, from 2004 to 2008, Dr Philip was president of Stryker Biotech, a division of Stryker. Dr Philip earned a bachelors of science in applied biology and a PhD in hematology and immunology from Trent Polytechnic (Nottingham Trent University), Nottingham, UK.
Dwight Sangrey, chairman of the board of Znomics, said: “We are excited to have someone of Mark’s caliber on the Znomics team and look forward to having him lead the company as we advance our three drug discovery programs and expand our collaborative partnerships.”